Chapter 23 of 25
What you will learn
- Understand the purpose of visits and examinations.
- Recognize when imaging or CA-125 may be useful.
- Prepare a survivorship plan and report symptoms between appointments.
What happens at follow-up?
Visits usually include a symptom review and examination, often including a pelvic examination when appropriate. The team asks about bleeding, pain, bowel or urinary changes, cough, appetite, weight and daily function. It should also address sexual health, menopause, lymphoedema, emotional wellbeing and treatment-related effects.
The schedule is usually closer together in the first few years, when recurrence risk is often greatest, and becomes less frequent later. Exact intervals differ by risk group, treatment, country and available services. Ask for a written plan rather than assuming that a schedule found online applies to you. Some follow-up may be shared with local clinicians if there is a clear route back to specialist care.
Scans and blood tests
Routine PET-CT at every visit is not recommended for an asymptomatic survivor without a specific indication. Imaging is useful when symptoms, examination or risk context raises a question that could change care. Selected high-risk situations may justify planned scans, but this is not a universal requirement.
CA-125 is not a reliable surveillance marker for every endometrial cancer. It may be considered if it was informative at diagnosis or in selected disease contexts. A normal result does not exclude recurrence, and an elevated value can have other causes. Routine vaginal cytology is not a substitute for examination and symptom assessment after endometrial cancer treatment.
Symptoms to report
| New or persistent symptom | Why to contact the team |
|---|---|
| Vaginal bleeding or blood-stained discharge | Needs assessment even after hysterectomy |
| Pelvic, abdominal or back pain | May reflect recurrence or a treatable non-cancer cause |
| Persistent cough or breathlessness | Requires evaluation rather than waiting for a scheduled scan |
| Unexplained weight loss, swelling or bowel/urinary change | Can guide targeted investigation |
Do not wait for the next routine appointment when a symptom is persistent, progressive or concerning. Sudden severe symptoms, heavy bleeding or marked breathlessness require urgent care. A symptom diary can help describe the pattern, but should not delay contacting the team.
Long-term health
Late effects may emerge months or years after treatment. Pelvic radiation can affect bowel, bladder, vaginal and bone health; surgery or radiation can contribute to lymphoedema; chemotherapy can leave neuropathy. Endocrine effects from immunotherapy can require long-term replacement treatment. These are legitimate reasons for follow-up even when there is no evidence of cancer.
Continue appropriate general preventive care, including cardiovascular and metabolic health, vaccinations and screening for other cancers according to age and risk. Confirmed Lynch syndrome requires a separate inherited-risk plan; ordinary cancer follow-up does not replace it. Smoking cessation, sustainable activity and good nutrition support recovery without guaranteeing that recurrence will never happen.
Your survivorship record
Keep the diagnosis, FIGO version and stage, molecular group, operation details, radiation summary and systemic treatments. Include ongoing medicines, late effects, genetics results and emergency contacts. This is especially useful when moving, travelling or seeing a clinician unfamiliar with your history.
Questions and take-home messages
Ask who coordinates follow-up, which symptoms require immediate contact and whether a test would change management. Fear of recurrence is common; counselling and practical coping strategies can help. More frequent scanning does not automatically provide better outcomes or lasting reassurance, while prompt assessment of meaningful symptoms remains important.
Related chapters
- Prognosis, Survival and Living Beyond Cancer
- Molecular Classification: The Four Major Groups
- How Doctors Choose Treatment
References and review status
- ESGO–ESTRO–ESP endometrial carcinoma guideline update, 2025
- NCI: Endometrial Cancer Treatment, patient version
- GeneReviews: Lynch Syndrome
- NCI: Side Effects of Cancer Treatment
Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy